Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Abstract Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Colorectal cancer KRAS G12C Prognosis Targeted therapy Combination therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a5cb9fa2bdcc4009ba782630d37a3d2e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5cb9fa2bdcc4009ba782630d37a3d2e
record_format	dspace
spelling	oai:doaj.org-article:a5cb9fa2bdcc4009ba782630d37a3d2e2021-11-07T12:02:42ZRole of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer10.1186/s12943-021-01441-41476-4598https://doaj.org/article/a5cb9fa2bdcc4009ba782630d37a3d2e2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12943-021-01441-4https://doaj.org/toc/1476-4598Abstract Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as a molecular switch to persistently stimulate downstream signaling pathways, including cell proliferation and survival, thereby leading to tumorigenesis. Patients whose CRC harbors KRAS mutations have a dismal prognosis. Currently, KRAS mutation testing is a routine clinical practice before treating metastatic cases, and the approaches developed to detect KRAS mutations have exhibited favorable sensitivity and accuracy. Due to the presence of KRAS mutations, this group of CRC patients requires more precise therapies. However, KRAS was historically thought to be an undruggable target until the development of KRASG12C allele-specific inhibitors. These promising inhibitors may provide novel strategies to treat KRAS-mutant CRC. Here, we provide an overview of the role of KRAS in the prognosis, diagnosis and treatment of CRC.Gongmin ZhuLijiao PeiHongwei XiaQiulin TangFeng BiBMCarticleColorectal cancerKRASG12CPrognosisTargeted therapyCombination therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENMolecular Cancer, Vol 20, Iss 1, Pp 1-17 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Colorectal cancer KRAS G12C Prognosis Targeted therapy Combination therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Colorectal cancer KRAS G12C Prognosis Targeted therapy Combination therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Gongmin Zhu Lijiao Pei Hongwei Xia Qiulin Tang Feng Bi Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
description	Abstract Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as a molecular switch to persistently stimulate downstream signaling pathways, including cell proliferation and survival, thereby leading to tumorigenesis. Patients whose CRC harbors KRAS mutations have a dismal prognosis. Currently, KRAS mutation testing is a routine clinical practice before treating metastatic cases, and the approaches developed to detect KRAS mutations have exhibited favorable sensitivity and accuracy. Due to the presence of KRAS mutations, this group of CRC patients requires more precise therapies. However, KRAS was historically thought to be an undruggable target until the development of KRASG12C allele-specific inhibitors. These promising inhibitors may provide novel strategies to treat KRAS-mutant CRC. Here, we provide an overview of the role of KRAS in the prognosis, diagnosis and treatment of CRC.
format	article
author	Gongmin Zhu Lijiao Pei Hongwei Xia Qiulin Tang Feng Bi
author_facet	Gongmin Zhu Lijiao Pei Hongwei Xia Qiulin Tang Feng Bi
author_sort	Gongmin Zhu
title	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
title_short	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
title_full	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
title_fullStr	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
title_full_unstemmed	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
title_sort	role of oncogenic kras in the prognosis, diagnosis and treatment of colorectal cancer
publisher	BMC
publishDate	2021
url	https://doaj.org/article/a5cb9fa2bdcc4009ba782630d37a3d2e
work_keys_str_mv	AT gongminzhu roleofoncogenickrasintheprognosisdiagnosisandtreatmentofcolorectalcancer AT lijiaopei roleofoncogenickrasintheprognosisdiagnosisandtreatmentofcolorectalcancer AT hongweixia roleofoncogenickrasintheprognosisdiagnosisandtreatmentofcolorectalcancer AT qiulintang roleofoncogenickrasintheprognosisdiagnosisandtreatmentofcolorectalcancer AT fengbi roleofoncogenickrasintheprognosisdiagnosisandtreatmentofcolorectalcancer
_version_	1718443566892580864

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Ejemplares similares